Last reviewed · How we verify
NCT05349019
A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease
trial testing Observational in Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene in 22 participants. Terminated before completion.
5 August 2022
Quick facts
| Lead sponsor | Escape Bio, Inc. |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 22 |
| Start date | 2 May 2022 |
| Primary completion | 5 August 2022 |
| Estimated completion | 5 August 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Observational — full drug profile →
Conditions studied
- Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene — all drugs for Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene →
Sponsor
Escape Bio, Inc.
Who can join
Adults 18 to 80, any sex, with Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To characterize using a participant centered decentralized (at home) study featuring wearable technology and telemedicine to study disease change over time in patients with PD caused by the G2019S mutation in the LRRK2 gene and to identify a clinical endpoint(s) for disease modifying experimental therapy trials.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Collaboration and knowledge integration for successful brain therapeutics - lessons learned from the pandemic.
Loza MI, Hmeljak J, Bountra C, Audia JE, et al · · 2022 · PMID 36541917 · DOI 10.1242/dmm.049755
Verify or expand the search:
- PubMed search for NCT05349019
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Observational
Trials testing the same drug.
- NCT07356700 — Deciphering the Factors of Longevity Through a Multi-Omics Study in Long-Lived Individuals in Hong Kong · not yet recruiting
- NCT07381751 — Artificial Intelligence-assisted MDS-UPDRS Assessment for Parkinson's Disease · not yet recruiting
- NCT07347574 — NeuroCare Community Project: A Community Based Prospective Observational Study for Early Alzheimer's Detection in HK · not yet recruiting
- NCT07338968 — A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma · not yet recruiting
- NCT06792994 — A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients Wi · not yet recruiting
Other Escape Bio, Inc. trials
Trials by the same sponsor.
- NCT04919356 — Parkinson's Disease G2019S LRRK2 Genetic Testing Program · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05349019 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Escape Bio, Inc.
- Last refreshed: 18 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05349019.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing